Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Public ClinicalTrials.gov record NCT02486718. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Study identification
- NCT ID
- NCT02486718
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,280 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Cisplatin Drug
- Vinorelbine Drug
- Docetaxel Drug
- Gemcitabine Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2015 (Actual)
- Primary completion
- Jan 26, 2024 (Actual)
- Completion
- Aug 26, 2026 (Actual)
- Last update posted
- Sep 30, 2026
2015 – 2026
United States locations
- U.S. sites
- 45
- U.S. states
- 20
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| California Cancer Associates for Research & Excellence, Inc. | Encinitas | California | 92024 | — |
| Compassionate Cancer Care Medical Group, Inc | Fountain Valley | California | 92708 | — |
| University of California Los Angeles | Los Angeles | California | 90024 | — |
| Southern California Permanente Medical Group Bellflower | Los Angeles | California | 90027 | — |
| Stanford University | Stanford | California | 94305 | — |
| Kaiser Permanente | Vallejo | California | 94589 | — |
| Kaiser Permanente - Walnut Creek | Walnut Creek | California | 94596 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| Lynn Cancer Institute - West | Boca Raton | Florida | 33486 | — |
| University of Miami School of Medicine - Sylvester at Deerfield | Deerfield Beach | Florida | 33442 | — |
| Holy Cross Hospital Inc | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists-Broadway, Fort Myers | Fort Myers | Florida | 33916 | — |
| SCRI Florida Cancer Specialists North | St. Petersburg | Florida | 33705 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta | Georgia | 30060 | — |
| Lewis Hall Singletary Oncology Center | Thomasville | Georgia | 31792 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Southern Illinois University, Simmons Cancer Institute | Springfield | Illinois | 62794 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40402 | — |
| St. Luke's Cancer Institute | Kansas City | Missouri | 64111 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89052 | — |
| Hematology Oncology Associates of Northern New Jersey | Florham Park | New Jersey | 07932 | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| Valley Hospital | Paramus | New Jersey | 07652 | — |
| Overlook Medical Center | Summit | New Jersey | 07901 | — |
| Clinical Research Alliance | Lake Success | New York | 11042 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Presbyterian Hospital | Charlotte | North Carolina | 28204 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| Oncology Hematology Care - SCRI | Cincinnati | Ohio | 45242 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Pinnacle Health | Harrisburg | Pennsylvania | 17109 | — |
| AHN Cancer Institute ? Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Chattanooga | Tennessee | 37403 | — |
| University Oncology Associates | Chattanooga | Tennessee | 37403 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Wellmont Medical Associates | Bristol | Virginia | 24201 | — |
| Hematology Oncology Associates of Fredericksburg, Inc. | Fredericksburg | Virginia | 22408 | — |
| MultiCare Regional Cancer Center - Auburn | Auburn | Washington | 98002-4117 | — |
| Providence Everett Med Ctr | Everett | Washington | 98201 | — |
| Swedish Medical Center | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 171 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02486718, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02486718 live on ClinicalTrials.gov.